Mega Genomics Limited
HHKEX:66677.18
HKD
+0.06
(+0.77%)
ISIN
KYG5960G1047
CUSIP
G5960G104
Return %
Stock
S&P 500
1Y
-0.35
14.20
3Y
-8.25
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Jing Jiang
- Full Time Employees
- 206
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- 401 Health Work Beijing BE China 100080
- IPO Date
- Jun 22, 2022
- Website
- megagenomics.cn
- Similar Companies
- Business
- Mega Genomics Limited is a China-based genetic testing platform company primarily engaged in consumer genetic testing and cancer screening services. Its core products and services include a broad range of genetic testing packages such as brain health assessment; alimentation capability assessment; Parkinson’s disease risk assessment; full-scale cancer risk assessment; cardiovascular and cerebrovascular disease risk assessment; hereditary breast and ovarian cancer testing; and screening tests for colorectal and gastric cancers using markers like Septin9 and RNF180. The company also develops specialized genetic testing kits including folate metabolic capacity assessment kits, ApoE gene testing kits for Alzheimer’s risk, BRCA1/BRCA2 gene mutation kits, Alzheimer's screening kits, lung nodule auxiliary diagnostic kits, cervical cancer screening kits, and other molecular diagnostics. Mega Genomics serves hospitals, health checkup centers, and research institutions, operating an advanced integrated technology platform system capable of processing up to 50,000 samples daily, positioning it as one of the largest in its industry. It operates primarily in China and is headquartered in Beijing. Founded in 2016, it functions through several subsidiaries under a consolidated corporate structure. Among the latest major company developments, Mega Genomics has established significant strategic framework agreements in 2024, including collaborations with Meinian OneHealth and Dr. Yu genetic testing services, aiming to expand its service offerings and customer reach through these partnerships. These agreements are projected to contribute considerable revenue growth and order volume increases for 2024 driven by expanded product matrices and diversified sample collection methods. Additionally, the company recently disclosed findings from an independent forensic investigation addressing revenue recognition issues related to genetic testing kits amid audit scrutiny, affirming no management misconduct was found. This investigation and ongoing review by the Hong Kong Stock Exchange underscore Mega Genomics' commitment to regulatory compliance and corporate governance. The company continues to develop and commercialize new in vitro diagnostic (IVD) products in its pipeline, including lung nodule auxiliary diagnosis, cervical cancer screening, and further genetic mutation tests to broaden its market offering and support preventive healthcare demands. Mega Genomics operates mainly in the healthcare and biotechnology sector focusing on genetic testing services for disease risk assessment, cancer screening, and preventive medical applications. Its target market includes consumers seeking personalized health risk assessments, hospitals, health checkup centers, and third-party research institutions. The company’s product portfolio and technology platforms reflect an emphasis on precision medicine and molecular diagnostics, addressing chronic diseases, hereditary cancers, and infectious diseases. Its ongoing strategic alliances and product innovation efforts are geared towards maintaining leadership in China’s growing genetic testing market while adhering to stringent regulatory standards. This description captures Mega Genomics Limited’s comprehensive business scope, recent strategic alliances, operational updates, and its market positioning based on the most current available information.